Abstract
A 73-year-old man with immunoglobulin (Ig)G kappa multiple myeloma is referred for outpatient transfusion due to severe anemia with hemoglobin (Hgb) of 6.6 g/dL. The patient has a history of red blood cell (RBC) transfusion at your hospital 2 years ago at which time the antibody screen was negative. An ethylenediaminetetraacetic acid (EDTA) anticoagulant sample is submitted to the blood bank for type and screen along with a request for two units of irradiated RBCs.
Keywords
Anti-CD38 Anti-CD47 Daratumumab Dithiothreitol/DTT Genotyping Multiple myeloma TrypsinReferences
- 1.Chapuy CI, Nicholson RT, Aquad MD, Chapuy B, Laubach JP, Richardson PG, et al. Resolving the daratumumab interference with blood compatibility testing. Transfusion. 2015;55(6 Pt 2):1545–54.CrossRefGoogle Scholar
- 2.DARZALEX® Prescribing Information. Janssen Biotech, Inc., Horsesham, PA; 2017.Google Scholar
- 3.Nedelcu E, Hall C, Stoner A, Eichbaum Q, Meena-Leist C. Interference of anti-CD47 therapy with blood bank testing. Transfusion. 2017;57(Suppl S3):148A.Google Scholar
- 4.Sher T, Fenton B, Akhtar A, Gertz MA. First report of safety and efficacy of daratumumab in two cases of advanced immunoglobulin light chain amyloidosis. Blood. 2016;128:1987–9.CrossRefGoogle Scholar
- 5.Bride KL, Vincent TL, Im S-Y, Aplenc R, Barrett DM, Carroll WL, et al. Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia (T-ALL). Blood. 2018;131:995–9.CrossRefGoogle Scholar
- 6.Chari A, Arinsburg SA, Jagannath S, Satta T, Treadwell I, Catemero D, et al. Blood transfusion management and transfusion-related outcomes in daratumumab-treated patients with relapsed or refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2018;18(1):44–51. http://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(17)30111-8/fulltext. Accessed 6 Jan 2018CrossRefGoogle Scholar
Recommended Reading
- Chari A, Arinsburg SA, Jagannath S, Satta T, Treadwell I, Catemero D, et al. Blood transfusion management and transfusion-related outcomes in daratumumab-treated patients with relapsed or refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2018;18(1):44–51. http://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(17)30111-8/fulltextCrossRefGoogle Scholar
Copyright information
© Springer International Publishing AG, part of Springer Nature 2018